GLP-1 Eye Risk: When Vision Changes Treatment
Morning Medical with Dr. Chow
A daily update covering the latest medical & health news from around the world using artificial intelligence. Doctor Chi-Ming Chow is a family physician, general internist, and cardiologist. He is also a Professor of Medicine at the University of Toronto.
Chi-Ming Chow
PodcastAI
PodcastAI

GLP-1 Eye Risk: When Vision Changes Treatment

E534 • Nov 19, 2026 • 22 mins

FDA warnings link GLP-1 drugs such as Ozempic and Wegovy to a possible risk of NAION, a rare condition that can cause sudden vision loss. Dr. Chi-Ming Chow examines how patients and doctors can weigh treatment benefits against this risk, who may need an MMR booster as measles returns, and why routine lipoprotein(a) screening remains debated.

Key Points

  • GLP 1 drugs like Ozempic and Wegovy now carry a warning about a rare but serious optic nerve condition, so any vision changes should prompt urgent discussion with both the eye doctor and the prescribing clinician.
  • Most adults do not need an MMR booster, but people with uncertain immunity or higher exposure risk such as healthcare workers, travelers, and those in outbreak areas should review their vaccination status.
  • Canada is facing rising flu activity and renewed measles control challenges while also gaining a new oral GLP 1 weight loss option, showing how prevention, surveillance, and treatment choices are all evolving at once.
Listen on Apple PodcastsListen on Spotify

Speakers

Chi-Ming Chow

Host • 100%

Transcript

Loading transcript...

- / -